{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:14:58Z","timestamp":1791234898661,"version":"4.1.0"},"reference-count":25,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sociedad Espa\u00f1ola de Neumologia SEPAR","award":["010.2018"],"award-info":[{"award-number":["010.2018"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Nebulised antibiotics are habitually used in patients with bronchiectasis, but the use of dry powder inhaled antibiotics (DPIA) in these patients is extremely limited. This study seeks to analyse the efficacy and safety of DPIA in bronchiectasis patients. Material and methods: Multi-centre study of historic cohorts. All the hospital centres in Spain were contacted in order to collect data on patients with a diagnosis of bronchiectasis who had taken at least one dose of DPIA. Its efficacy was analysed in clinical, functional and microbiological terms by comparing the year before and the year after the prescription of DPIA. Adverse effects and variables associated with these effects, or any need to withdraw the drug, were also analysed. Results: 164 patients from 33 Spanish centres were included; 86% and 14% of these were treated with dry powder colistin and tobramycin, respectively. Chronic bronchial infection by Pseudomonas aeruginosa was present in 86% of these patients, and DPIA significantly reduced the number of exacerbations, the quantity and purulence of sputum and the isolation of pathogenic microorganisms. The most common adverse effect was cough (40%), particularly in cases of Chronic Obstructive Pulmonary Disease (COPD) and a previous cough and in those patients who had difficulties in handling the device. These factors were associated with a higher level of withdrawal of the treatment. There were no serious adverse effects. Conclusions: Our study suggests that DPIA are clinically efficacious and safe for treating bronchiectasis patients. Cough was shown to be the most common side-effect and reason for withdrawal of the treatment.<\/jats:p>","DOI":"10.3390\/jcm9072317","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T03:23:16Z","timestamp":1595388196000},"page":"2317","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Inhaled Dry Powder Antibiotics in Patients with Non-Cystic Fibrosis Bronchiectasis: Efficacy and Safety in a Real-Life Study"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7321-1891","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Mart\u00ednez-Garc\u00eda","sequence":"first","affiliation":[{"name":"Pneumology Department, Hospital Universitario y Polit\u00e9cnico La Fe, 46026 Valencia, Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2121-7554","authenticated-orcid":false,"given":"Grace","family":"Oscullo","sequence":"additional","affiliation":[{"name":"Pneumology Department, Hospital Universitario y Polit\u00e9cnico La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Barreiro","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Pneumology Department, Hospital del Mar-IMIM., 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5367-3335","authenticated-orcid":false,"given":"Selene","family":"Cuenca","sequence":"additional","affiliation":[{"name":"Pneumology Department, Hospital General de Castell\u00f3n, 12004 astell\u00f3, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2422-0644","authenticated-orcid":false,"given":"Angela","family":"Cervera","sequence":"additional","affiliation":[{"name":"Pneumology Department, Hospital General Universitario de Valencia, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Padilla-Galo","sequence":"additional","affiliation":[{"name":"Pneumology Department, Hospital Costa del Sol, 29604 Marbella, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0753-1771","authenticated-orcid":false,"given":"David","family":"de la Rosa","sequence":"additional","affiliation":[{"name":"Pneumology Department, Hospital Universitario Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Navarro","sequence":"additional","affiliation":[{"name":"Pneumology Department, Hospital Universitario Mutua Terrassa, 08221 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Giron","sequence":"additional","affiliation":[{"name":"Pneumology Department, Hospital Univesitario la Princesa, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Carbonero","sequence":"additional","affiliation":[{"name":"Pneumology Department, Hospital de Jerez, 11407 C\u00e1diz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Castro Otero","sequence":"additional","affiliation":[{"name":"Pneumology Department, Hospital Central de la Defensa Gomez Ulla, 28028 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8007-9323","authenticated-orcid":false,"given":"Francisco","family":"Casas","sequence":"additional","affiliation":[{"name":"Pneumology Department, Hospital Universitario San Cecilio, 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Maselli, D.J., Keyt, H., and Restrepo, M.I. (2017). Inhaled Antibiotic Therapy in Chronic Respiratory Diseases. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18051062"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Martinez-Garc\u00eda, M.A., Villa, C., Dobarganes, Y., Gir\u00f3n, R., Ma\u00edz, L., Garc\u00eda-Clemente, M., Sibila, O., Golpe, R., Rodr\u00edguez, J., and Barreiro, E. (2020). RIBRON: The spanish Online Bronchiectasis Registry. In Characterization of the First 1912 Patients. Arch. Bronconeumol.","DOI":"10.1016\/j.arbr.2020.11.010"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.arbres.2017.07.016","article-title":"Normativa para el tratamiento de las bronquiectasias en el adulto","volume":"54","author":"Olveira","year":"2018","journal-title":"Arch. Bronconeumol."},{"key":"ref_4","first-page":"50","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"9","author":"Polverino","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e000348","DOI":"10.1136\/bmjresp-2018-000348","article-title":"British Thoracic Society guideline for bronchiectasis in adults","volume":"5","author":"Hill","year":"2019","journal-title":"BMJ Open Raxespir. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: A phase II randomised study","volume":"41","author":"Wilson","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Waterer, G., Lord, J., Hofmann, T., and Jouhikainen, T. (2020). Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: A New Approach to Therapy for Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.01776-19"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Hoppentocht, M., Akkerman, O.W., Hagedoorn, P., Alffenaar, J.-W.C., Van Der Werf, T.S., Kerstjens, H.A., Frijlink, H.W., and De Boer, A.H. (2016). Tolerability and Pharmacokinetic. Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0149768"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40265-014-0181-0","article-title":"Colistimethate sodium dry powder for inhalation: A review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis","volume":"74","author":"Conole","year":"2014","journal-title":"Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.5603\/ARM.2017.0061","article-title":"Dry powder inhalers\u2014Between the doctor and he patient","volume":"86","author":"Emeryk","year":"2018","journal-title":"Adv. Respir. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/MCP.0000000000000109","article-title":"Dry powder inhalers in cystic fibrosis: Same old drugs but different benefits?","volume":"20","author":"Uttley","year":"2014","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.arbres.2017.07.015","article-title":"Normativa para la valoraci\u00f3n y diagn\u00f3stico de las bronquiectasias en el adulto","volume":"54","author":"Olveira","year":"2018","journal-title":"Arch. Bronconeumol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1702052","DOI":"10.1183\/13993003.02053-2017","article-title":"RESPIRE 1: A phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1702053","DOI":"10.1183\/13993003.02053-2017","article-title":"RESPIRE 2: A phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Freedom Study Group. Safety and efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: A randomised study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jcf.2006.10.010","article-title":"Dry powder inhalation of colistin in cystic fibrosis patients: A single dose pilot study","volume":"6","author":"Westerman","year":"2007","journal-title":"J. Cyst. Fibros."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S2213-2600(19)30335-2","article-title":"Cystic fibrosis lung disease and bronchiectasis","volume":"8","author":"Chalmers","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1378\/chest.113.5.1329","article-title":"Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase, I","volume":"113","author":"Barker","year":"1998","journal-title":"Chest"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"65S","DOI":"10.1378\/chest.107.2_Supplement.65S","article-title":"Aerosolized recombinant human DNase I for the treatment of cystic fibrosis","volume":"107","author":"Shak","year":"1995","journal-title":"Chest"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): Two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jcf.2014.06.003","article-title":"Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study","volume":"14","author":"Tiddens","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1183\/09031936.00026313","article-title":"Multidimensional approach to non-cystic fibrosis bronchiectasis: The FACED score","volume":"43","author":"Relat","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Von Schantz, S., Katajavuori, N., and Juppo, A.M. (2018). The Use of Video Instructions in Patient Education Promoting Correct Technique for Dry Powder Inhalers: An Investigation on Inhaler-Na\u00efve Individuals. Pharmacy, 6.","DOI":"10.3390\/pharmacy6040106"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40248-016-0057-0","article-title":"Need of education for dry powder inhaler storage and retention\u2014A patient-reported survey","volume":"11","author":"Telg","year":"2016","journal-title":"Multidiscip. Respir. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1053\/rmed.2000.0834","article-title":"A ten year review of colomycin","volume":"94","author":"Littlewood","year":"2000","journal-title":"Respir. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/7\/2317\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:50:25Z","timestamp":1760176225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/7\/2317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["jcm9072317"],"URL":"https:\/\/doi.org\/10.3390\/jcm9072317","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,21]]}}}